Solventum (SOLV) closed at $88.62 on November 11, 2026, down 1.6% from the previous close, on volume of 689,895 shares (30-day average 1,165,773).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Modified Iron Condor or Double Vertical | 20-Nov-2675[11x]P : 85[11x]P : 90[8x]C : 105[5x]C | 3,500 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
UBS Sticks to Its Buy Rating for Solventum Corporation (SOLV)
TipRanks (Mon, 9-Nov 8:57 AM ET)
Solventum Reports Third Quarter 2026 Financial Results
PRNewswire (Thu, 5-Nov 4:05 PM ET)
PRNewswire (Mon, 19-Oct 4:05 PM ET)
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
PRNewswire (Thu, 15-Oct 4:05 PM ET)
Wound Care Stocks Are Posting Double-Digit Growth. Here's Why.
Globe Newswire (Tue, 6-Oct 9:06 AM ET)
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
PRNewswire (Wed, 2-Sep 4:06 PM ET)
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
Globe Newswire (Wed, 12-Aug 9:15 AM ET)
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and infection prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Solventum trades on the NYSE stock market under the symbol SOLV.
As of November 12, 2026, SOLV stock price climbed to $89.05 with 111,205 million shares trading.
SOLV has a beta of 0.20, meaning it tends to be less sensitive to market movements. SOLV has a correlation of 0.01 to the broad based SPY ETF.
SOLV has a market cap of $15.16 billion. This is considered a Large Cap stock.
Last quarter Solventum reported $2 billion in Revenue and $1.45 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.10.
The top ETF exchange traded funds that SOLV belongs to (by Net Assets): VTI, VOO, VB, RSP, VBR.
SOLV has outperformed the market in the last year with a price return of +20.5% while the SPY ETF gained +12.5%. SOLV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.9% and +8.8%, respectively, while the SPY returned -1.0% and -1.5%, respectively.
SOLV support price is $86.79 and resistance is $90.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SOLV shares will trade within this expected range on the day.
